Blogs

Latest Blogs

EBF OS 2025: My Key Highlights

December 10, 2025

A unifying message across EBF 2025 was that bioanalytical science is transitioning from technical execution to decision support. For years, our industry has focused on…

Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials

October 18, 2024

Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…

Allogeneic CAR T cell therapies: A major step forward

October 9, 2024

In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…

A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology

September 17, 2024

Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…

The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers

September 5, 2024

Following Covid-19, the world is collectively on high alert for anything that could indicate another pandemic. What do we know…

The STING in the tail: How our own defense mechanisms to infection may be working against us

August 29, 2024

In this latest blog, we explore this pathway, its burgeoning links to multiple diseases and how biomarker profiling can assist…

Falling drug approval rates: What should we be doing differently?

August 6, 2024

Over the years, this failure rate of drug approvals has not seen significant improvement, which begs the question - why?…